The energy-less red blood cell is lost: Erythrocyte enzyme abnormalities of glycolysis

Blood

Volumn 106, Issue 13, 2005, Pages 4034-4042

  Van Wijk, Richard ^a   Van Solinge, Wouter W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ENOLASE; ERYTHROCYTE ENZYME; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEXOKINASE; LACTATE DEHYDROGENASE; PHOSPHATE; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE MUTASE; PYRUVATE KINASE; TRIOSEPHOSPHATE ISOMERASE;

BIOCHEMISTRY; CELL LOSS; CELL SURVIVAL; ENZYME DEFECT; ERYTHROCYTE; GLYCOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INBORN ERROR OF METABOLISM; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 28844488320     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1622     Document Type: Review

References (113)

1. Surgenor DM. The Red Blood Cell. New York, NY: Academic Press; 1974.
2. Benesch R, Benesch RE. The effect of organic phosphates from the human erythrocyte on the allosteric properties of hemoglobin. Biochem Biophys Res Commun. 1967;26:162-167.
3. Miwa S. Hereditary disorders of red cell enzymes in the Embden-Meyerhof pathway. Am J Hematol. 1983;14:381-391.
4. Valentine WN, Tanaka KR, Paglia DE. Hemolytic anemias and erythrocyte enzymopathies. Ann Intern Med. 1985;103:245-257.
5. Beutler E. The molecular biology of G6PD variants and other red cell enzyme defects. Annu Rev Med. 1992;43:47-59.
6. Arya R, Layton DM, Bellingham AJ. Hereditary red cell enzymopathies. Blood Rev. 1995;9:165-175.
7. Valentine WN, Paglia DE. The primary cause of hemolysis in enzymopathies of anaerobic glycolysis: a viewpoint. Blood Cells. 1980;6:819-829.
8. Martinov MV, Plotnikov AG, Vitvitsky VM, Ataullakhanov FI. Deficiencies of glycolytic enzymes as a possible cause of hemolytic anemia. Biochim Biophys Acta. 2000;1474:75-87.
9. Beutler E. The relationship of red cell enzymes to red cell life-span. Blood Cells. 1988;14:69-91.
10. Beutler E. Selectivity of proteases as a basis for tissue distribution of enzymes in hereditary defi-ciencies. Proc Natl Acad Sci U S A. 1983;80:3767-3768.
11. Kahn A. Abnormalities of erythrocyte enzymes in dyserythropoiesis and malignancies. Clin Haematol. 1981;10:123-138.
12. Eber SW. Disorders of erythrocyte glycolysis and nucleotide metabolism. In: Handin RI, Lux SE, Stossel TP, eds. Blood Principles and Practice of Hematology. 2d ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:1887-1914.
13. Griffin LD, Gelb BD, Wheeler DA, Davison D, Adams V, McCabe ER. Mammalian hexokinase 1: evolutionary conservation and structure to function analysis. Genomics. 1991;11:1014-1024.
14. Wilson JE. Hexokinases. Rev Physiol Biochem Pharmacol. 1995;126:65-198.
15. Cárdenas ML, Cornish-Bowden A, Ureta T. Evolution and regulatory role of the hexokinases. Biochim Biophys Acta. 1998;1401:242-264.
16. Aleshin AE, Zeng C, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB. The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate. Structure. 1998;6:39-50.
17. Mulichak AM, Wilson JE, Padmanabhan K, Garavito RM. The structure of mammalian hexokinase-1. Nat Struct Biol. 1998;5:555-560.
18. R). Blood. 1990;75:770-775.
19. Andreoni F, Ruzzo A, Magnani M. Structure of the 5′ region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA. Biochim Biophys Acta. 2000;1493:19-26.
20. R isozyme: organization of the hexokinase I gene, the erythroid-specific promoter, and transcription initiation site. Mol Genet Metab. 1999;67:118-130.
21. Murakami K, Piomelli S. Identification of the cDNA for human red blood cell-specific hexokinase isozyme. Blood. 1997;89:762-766.
22. Kanno H. Hexokinase: gene structure and mutations. Baillieres Best Pract Res Clin Haematol. 2000;13:83-88.
23. Bianchi M, Magnani M. Hexokinase mutations that produce nonspherocytic hemolytic anemia. Blood Cells Mol Dis. 1995;21:2-8.
24. Kanno H, Murakami K, Hariyama Y, Ishikawa K, Miwa S, Fujii H. Homozygous intragenic deletion of type I hexokinase gene causes lethal hemolytic anemia of the affected fetus [letter]. Blood. 2002;100:1930.
25. van Wijk R, Rijksen G, Huizinga EG, Nieuwenhuis HK, van Solinge WW. HK Utrecht: missense mutation in the active site of human hexokinase associated with hexokinase deficiency and severe nonspherocytic hemolytic anemia. Blood. 2003;101:345-347.
26. I) deficiency. Blood Cells Mol Dis. 2001;27:850-860.
27. Sriram G, Martinez JA, McCabe ER, Liao JC, Dipple KM. Single-gene disorders: what role could moonlighting enzymes play? Am J Hum Genet. 2005;76:911-924.
28. West JD, Flockhart JH, Peters J, Ball ST. Death of mouse embryos that lack a functional gene for glucose phosphate isomerase. Genet Res. 1990;56:223-236.
29. Read J, Pearce J, Li X, Muirhead H, Chirgwin J, Davies C. The crystal structure of human phosphoglucose isomerase at 1.6 Å resolution: implications for catalytic mechanism, cytokine activity and haemolytic anaemia. J Mol Biol. 2001;309:447-463.
30. Xu W, Lee P, Beutler E. Human glucose phosphate isomerase: exon mapping and gene structure. Genomics. 1995;29:732-739.
31. Kugler W, Lakomek M. Glucose-6-phosphate isomerase deficiency. Baillieres Best Pract Res Clin Haematol. 2000;13:89-101.
32. Matthay KK, Mentzer WC. Erythrocyte enzymopathies in the newborn. Clin Haematol. 1981;10:31-55.
33. Schröter W, Eber SW, Bardosi A, Gahr M, Gabriel M, Sitzmann FC. Generalised glucosephosphate isomerase (GPI) deficiency causing haemolytic anaemia, neuromuscular symptoms and impairment of granulocytic function: a new syndrome due to a new stable GPI variant with diminished specific activity (GPI Homburg). Eur J Pediatr. 1985;144:301-305.
34. Merkle S, Pretsch W. Glucose-6-phosphate isomerase deficiency associated with nonspherocytic hemolytic anemia in the mouse: an animal model for the human disease. Blood. 1993;81:206-213.
35. Layzer RB, Rowland LP, Bank WJ. Physical and kinetic properties of human phosphofructokinase from skeletal muscle and erythrocytes. J Biol Chem. 1969;244:3823-3831.
36. Vora S. Isozymes of human phosphofructokinase: biochemical and genetic aspects. Isozymes Curr Top Biol Med Res. 1983;11:3-23.
37. Vora S, Durham S, de Martinville B, George DL, Francke U. Assignment of the human gene for muscle-type phosphofructokinase (PFKM) to chromosome 1 (region cen leads to q32) using somatic cell hybrids and monoclonal anti-M antibody. Somatic Cell Genet. 1982;8:95-104.
38. Yamada S, Nakajima H, Kuehn MR. Novel testisand embryo-specific isoforms of the phosphofructokinase-1 muscle type gene. Biochem Biophys Res Commun. 2004;316:580-587.
39. Elson A, Levanon D, Brandeis M, et al. The structure of the human liver-type phosphofructokinase gene. Genomics. 1990;7:47-56.
40. Fujii H, Miwa S. Other erythrocyte enzyme defi-ciencies associated with non-haematological symptoms: phosphoglycerate kinase and phosphofructokinase deficiency. Baillieres Best Pract Res Clin Haematol. 2000;13:141-148.
41. Raben N, Sherman J, Miller F, Mena H, Plotz P. A 5′ splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease). J Biol Chem. 1993;268:4963-4967.
42. Sherman JB, Raben N, Nicastri C, et al. Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII - and their population frequency. Am J Hum Genet. 1994;55:305-313.
43. Smith BF, Stedman H, Rajpurohit Y, et al. Molecular basis of canine muscle type phosphofructokinase deficiency. J Biol Chem. 1996;271:20070-20074.
44. Gamblin SJ, Davies GJ, Grimes JM, Jackson RM, Littlechild JA, Watson HC. Activity and speci-ficity of human aldolases. J Mol Biol. 1991;219:573-576.
45. Izzo P, Costanzo P, Lupo A, Rippa E, Paolella G, Salvatore F. Human aldolase A gene: structural organization and tissue-specific expression by multiple promoters and alternate mRNA processing. Eur J Biochem. 1988;174:569-578.
46. Beutler E, Scott S, Bishop A, Margolis N, Matsumoto F, Kuhl W. Red cell aldolase deficiency and hemolytic anemia: a new syndrome. Trans Assoc Am Physicians. 1973;86:154-166.
47. Miwa S, Fujii H, Tani K, et al. Two cases of red cell aldolase deficiency associated with hereditary hemolytic anemia in a Japanese family. Am J Hematol. 1981;11:425-437.
48. Kreuder J, Borkhardt A, Repp R, et al. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med. 1996;334:1100-1104.
49. Yao DC, Tolan DR, Murray MF, et al. Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr). Blood. 2004;103:2401-2403.
50. Esposito G, Vitagliano L, Costanzo P, et al. Human aldolase A natural mutants: relationship between flexibility of the C-terminal region and enzyme function. Biochem J. 2004;380:51-56.
51. Kishi H, Mukai T, Hirono A, Fujii H, Miwa S, Hori K. Human aldolase A deficiency associated with a hemolytic anemia: thermolabile aldolase due to a single base mutation. Proc Natl Acad Sci U S A. 1987;84:8623-8627.
52. Mande SC, Mainfroid V, Kalk KH, Goraj K, Martial JA, Hol WG. Crystal structure of recombinant human triosephosphate isomerase at 2.8 Å resolution: triosephosphate isomerase-related human genetic disorders and comparison with the trypanosomal enzyme. Protein Sci. 1994;3:810-821.
53. Peters J, Hopkinson DA, Harris H. Genetic and non-genetic variation of triose phosphate isomerase isozymes in human tissues. Ann Hum Genet. 1973;36:297-312.
54. Brown JR, Daar IO, Krug JR, Maquat LE. Characterization of the functional gene and several processed pseudogenes in the human triosephosphate isomerase gene family. Mol Cell Biol. 1985;5:1694-1706.
55. Orosz F, Wagner G, Liliom K, et al. Enhanced association of mutant triosephosphate isomerase to red cell membranes and to brain microtubules. Proc Natl Acad Sci U S A. 2000;97:1026-1031.
56. Schneider AS. Triosephosphate isomerase defi-ciency: historical perspectives and molecular aspects. Baillieres Best Pract Res Clin Haematol. 2000;13:119-140.
57. Rosa R, Prehu MO, Calvin MC, Badoual J, Alix D, Girod R. Hereditary triose phosphate isomerase deficiency: seven new homozygous cases. Hum Genet. 1985;71:235-240.
58. Hollán S, Magócsi M, Fodor E, Horányi M, Harsányi V, Farkas T. Search for the pathogenesis of the differing phenotype in two compound heterozygote Hungarian brothers with the same genotypic triosephosphate isomerase deficiency. Proc Natl Acad Sci U S A. 1997;94:10362-10366.
59. Daar IO, Artymiuk PJ, Phillips DC, Maquat LE. Human triose-phosphate isomerase deficiency: a single amino acid substitution results in a thermolabile enzyme. Proc Natl Acad Sci U S A. 1986;83:7903-7907.
60. Orosz F, Oláh J, Alvarez M, et al. Distinct behavior of mutant triosephosphate isomerase in hemolysate and in isolated form: molecular basis of enzyme deficiency. Blood. 2001;98:3106-3112.
61. Schneider A, Westwood B, Yim C, et al. The 1591C mutation in triosephosphate isomerase (TPI) deficiency: tightly linked polymorphisms and a common haplotype in all known families. Blood Cells Mol Dis. 1996;22:115-125.
62. Zingg BC, Pretsch W, Mohrenweiser HW. Molecular analysis of four ENU induced triosephosphate isomerase null mutants in Mus musculus. Mutat Res. 1995;328:163-173.
63. McCarrey JR, Thomas K. Human testis-specific PGK gene lacks introns and possesses characteristics of a processed gene. Nature. 1987;326:501-505.
64. Huang IY, Welch CD, Yoshida A. Complete amino acid sequence of human phosphoglycerate kinase: cyanogen bromide peptides and complete amino acid sequence. J Biol Chem. 1980;255:6412-6420.
65. Banks RD, Blake CC, Evans PR, et al. Sequence, structure and activity of phosphoglycerate kinase: a possible hinge-bending enzyme. Nature. 1979;279:773-777.
66. Bernstein BE, Michels PA, Hol WG. Synergistic effects of substrate-induced conformational changes in phosphoglycerate kinase activation. Nature. 1997;385:275-278.
67. Michelson AM, Blake CC, Evans ST, Orkin SH. Structure of the human phosphoglycerate kinase gene and the intron-mediated evolution and dispersal of the nucleotide-binding domain. Proc Natl Acad Sci U S A. 1985;82:6965-6969.
68. Tsujino S, Shanske S, DiMauro S. Molecular genetic heterogeneity of phosphoglycerate kinase (PGK) deficiency. Muscle Nerve. 1995;3:S45-S49.
69. Ookawara T, Dave V, Willems P, et al. Retarded and aberrant splicings caused by single exon mutation in a phosphoglycerate kinase variant. Arch Biochem Biophys. 1996;327:35-40.
70. Kanno H, Fujii H, Miwa S. Structural analysis of human pyruvate kinase L-gene and identification of the promoter activity in erythroid cells. Biochem Biophys Res Commun. 1992;188:516-523.
71. Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J Biol Chem. 1987;262:14366-14371.
72. Tani K, Fujii H, Nagata S, Miwa S. Human liver type pyruvate kinase: complete amino acid sequence and the expression in mammalian cells. Proc Natl Acad Sci U S A. 1988;85:1792-1795.
73. Lenzner C, Nürnberg P, Jacobasch G, Thiele B-J. Complete genomic sequence of the human PK-L/R-gene includes four intragenic polymorphisms defining different haplotype backgrounds of normal and mutant PK-genes. DNA Seq. 1997;8:45-53.
74. 2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem. 1986;261:13807-13812.
75. 2- to L-type during development of the red cell. Br J Haematol. 1983;54:467-474.
76. Max-Audit I, Testa U, Kechemir D, Titeux M, Vainchenker W, Rosa R. Pattern of pyruvate kinase isozymes in erythroleukemia cell lines and in normal human erythroblasts. Blood. 1984;64:930-936.
77. Max-Audit I, Kechemir D, Mitjavila MT, Vainchenker W, Rotten D, Rosa R. Pyruvate kinase synthesis and degradation by normal and pathologic cells during erythroid maturation. Blood. 1988;72:1039-1044.
78. Nakashima K. Further evidence of molecular alteration and aberration of erythrocyte pyruvate kinase. Clin Chim Acta. 1974;55:245-254.
79. Kahn A, Marie J. Pyruvate kinases from human erythrocytes and liver. Methods Enzymol. 1982;90:131-140.
80. Staal GEJ, Koster JF, Kamp H, van Milligen-Boersma L, Veeger C. Human erythrocyte pyruvate kinase: its purification and some properties. Biochim Biophys Acta. 1971;227:86-96.
81. Gupta RK, Oesterling RM. Dual divalent cation requirement for activation of pyruvate kinase; essential roles of both enzyme- and nucleotidebound metal ions. Biochemistry. 1976;15:2881-2887.
82. Valentini G, Chiarelli LR, Fortin R, et al. Structure and function of human erythrocyte pyruvate kinase: molecular basis of nonspherocytic hemolytic anemia. J Biol Chem. 2002;277:23807-23814.
83. Enriqueta Muñoz M, Ponce E. Pyruvate kinase: current status of regulatory and functional properties. Comp Biochem Physiol B Biochem Mol Biol. 2003;135:197-218.
84. Valentini G, Chiarelli L, Fortin R, Speranza ML, Galizzi A, Mattevi A. The allosteric regulation of pyruvate kinase. J Biol Chem. 2000;275:18145-18152.
85. Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 1998;6:195-210.
86. Wooll JO, Friesen RHE, White MA, et al. Structural and functional linkages between subunit interfaces in mammalian pyruvate kinase. J Mol Biol. 2001;312:525-540.
87. Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood. 2000;95:3585-3588.
88. Delivoria-Papadopoulos M, Oski FA, Gottlieb AJ. Oxygen-hemoglobulin dissociation curves: effect of inherited enzyme defects of the red cell. Science. 1969;165:601-602.
89. Ferreira P, Morais L, Costa R, et al. Hydrops fetalis associated with erythrocyte pyruvate kinase deficiency. Eur J Pediatr. 2000;159:481-482.
90. Kanno H, Wei DC, Chan LC, et al. Hereditary hemolytic anemia caused by diverse point mutations of pyruvate kinase gene found in Japan and Hong Kong. Blood. 1994;84:3505-3509.
91. Lenzner C, Nurnberg P, Jacobasch G, Gerth C, Thiele BJ. Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia. Blood. 1997;89:1793-1799.
92. Diez A, Gilsanz F, Martinez J, Perez-Benavente S, Meza NW, Bautista JM. Life threatening nonspherocytic haemolytic anaemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression. Blood. Prepublished on May 3, 2005, as DOI 10.1182/blood-2005-02-0555.
93. Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol. 2005;130:11-25.
94. van Wijk R, van Solinge WW, Nerlov C, et al. Disruption of a novel regulatory element in the erythroid-specific promoter of the human PKLR gene causes severe pyruvate kinase deficiency. Blood. 2003;101:1596-1602.
95. Whitney KM, Goodman SA, Bailey EM, Lothrop CD Jr. The molecular basis of canine pyruvate kinase deficiency. Exp Hematol. 1994;22:866-874.
96. slc mice with a point mutation of the gene encoding red blood cell type pyruvate kinase. Blood. 1998;91:2169-2174.
97. Min-Oo G, Fortin A, Tam M-F, Nantel A, Stevenson MM, Gros P. Pyruvate kinase deficiency in mice protects against malaria. Nat Genet. 2003;35:357-362.
98. Harkness DR. A new erythrocytic enzyme defect with hemolytic anemia: glyceraldehyde-3-phosphate dehydrogenase deficiency [abstract]. J Lab Clin Med. 1966;68:879-880.
99. Oski FA, Whaun J. Hemolytic anemia and red cell glyceraldehyde-3- phosphate dehydrogenase (G-3-PD) deficiency [abstract]. Clin Res. 1969;17:427.
100. Stefanini M. Chronic hemolytic anemia associated with erythrocyte enolase deficiency exacerbated by ingestion of nitrofurantoin. Am J Clin Pathol. 1972;58:408-414.
101. Boulard-Heitzmann P, Boulard M, Tallineau C, et al. Decreased red cell enolase activity in a 40-year-old woman with compensated haemolysis. Scand J Haematol. 1984;33:401-404.
102. Rosa R, Calvin MC, Prehu MO, Arous N. Purification of human erythrocyte phosphoglyceromutase. J Chromatogr. 1984;285:203-209.
103. de Atauri P, Repiso A, Oliva B, Vives-Corrons JL, Climent F, Carreras J. Characterization of the first described mutation of human red blood cell phosphoglycerate mutase. Biochim Biophys Acta. 2005;1740:403-410.
104. Miwa S, Nishina T, Kakehashi Y, Kitamura M, Hiratsuka A. Studies on erythrocyte metabolism in a case with hereditary deficiency of H-subunit of lactate dehydrogenase. Acta Haematol Jpn. 1971;34:228-232.
105. Kremer JP, Datta T, Pretsch W, Charles DJ, Dormer P. Mechanisms of compensation of hemolytic anemia in a lactate dehydrogenase mouse mutant. Exp Hematol. 1987;15:664-670.
106. Benesch RE, Benesch R, Yu CI. The oxygenation of hemoglobin in the presence of 2,3-diphosphoglycerate: effect of temperature, pH, ionic strength, and hemoglobin concentration. Biochemistry. 1969;8:2567-2571.
107. Rosa R, Gaillardon J, Rosa J. Diphosphoglycerate mutase and 2,3-diphosphoglycerate phosphatase activities of red cells: comparative electrophoretic study. Biochem Biophys Res Commun. 1973;51:536-542.
108. Hass LF, Kappel WK, Miller KB, Engle RL. Evidence for structural homology between human red cell phosphoglycerate mutase and 2,3-bisphosphoglycerate synthase. J Biol Chem. 1978;253:77-81.
109. Wang Y, Wei Z, Bian Q, et al. Crystal structure of human bisphosphoglycerate mutase. J Biol Chem. 2004;279:39132-39138.
110. Joulin V, Peduzzi J, Romeo PH, et al. Molecular cloning and sequencing of the human erythrocyte 2,3-bisphosphoglycerate mutase cDNA: revised amino acid sequence. EMBO J. 1986;5:2275-2283.
111. Rosa R, Prehu MO, Beuzard Y, Rosa J. The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes. J Clin Invest. 1978;62:907-915.
112. Lemarchandel V, Joulin V, Valentin C, et al. Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood. 1992;80:2643-2649.
113. Hoyer JD, Allen SL, Beutler E, Kubik K, West C, Fairbanks VF. Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Am J Hematol. 2004;75:205-208.